Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Drugs & Therapy Perspectives

04-01-2025 | Migraine | Adis Drug Q&A

Zavegepant nasal spray in the acute treatment of migraine: a profile of its use

Author: Yahiya Y. Syed

Published in: Drugs & Therapy Perspectives

Login to get access

Abstract

Zavegepant nasal spray (ZAVZPRET®) is the first intranasal calcitonin gene-related peptide (CGRP) receptor antagonist approved in the USA for the acute treatment of migraine with or without aura in adults. It is a valuable option for these patients, particularly for those who prefer nonoral medications, are unable to take oral treatments due to nausea, vomiting or other gastrointestinal comorbidities, or need rapid relief from migraine symptoms. In clinical trials, a single zavegepant nasal spray resulted in significantly more patients achieving freedom from pain and freedom from the most bothersome symptom (light sensitivity, sound sensitivity or nausea) at 2 h postdose compared with placebo. The nasal spray offers pain relief within 15 min of administration, return to normal function in 30 min, and sustained relief for up to 48 h. It is generally well tolerated, with taste disorders being the most common adverse reaction. Zavegepant nasal spray remains well-tolerated in the long term (when used up to eight times per month for 1 year) with no safety signals.
Appendix
Available only for authorised users
Literature
1.
Headache Classification Committee of the International Headache Society (IHS). The international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1-211.
2.
Gawde P, Shah H, Patel H, et al. Revisiting migraine: the evolving pathophysiology and the expanding management armamentarium. Cureus. 2023;15(2): e34553.PubMedPubMedCentral
3.
Tfelt-Hansen P, De Vries P, Saxena PR. Triptans in migraine: a comparative review of pharmacology, pharmacokinetics and efficacy. Drugs. 2000;60(6):1259–87.CrossRefPubMed
4.
Ailani J, Burch RC, Robbins MS, et al. The American Headache Society consensus statement: update on integrating new migraine treatments into clinical practice. Headache. 2021;61(7):1021–39.CrossRefPubMed
5.
Leroux E, Buchanan A, Lombard L, et al. Evaluation of patients with insufficient efficacy and/or tolerability to triptans for the acute treatment of migraine: a systematic literature review. Adv Ther. 2020;37(12):4765–96.CrossRefPubMedPubMedCentral
6.
7.
Tajti J, Szok D, Csáti A, et al. The pharmacotherapeutic management of episodic and chronic migraine with gepants. Expert Opin Pharmacother. 2023;24(8):947–58.CrossRefPubMed
8.
9.
Yang CP, Liang CS, Chang CM, et al. Comparison of new pharmacologic agents with triptans for treatment of migraine: a systematic review and meta-analysis. JAMA Netw Open. 2021;4(10): e2128544.CrossRefPubMedPubMedCentral
10.
Edvinsson L, Warfvinge K. Recognizing the role of CGRP and CGRP receptors in migraine and its treatment. Cephalalgia. 2019;39(3):366–73.CrossRefPubMed
11.
Smelt AF, Louter MA, Kies DA, et al. What do patients consider to be the most important outcomes for effectiveness studies on migraine treatment? results of a Delphi study. PLoS ONE. 2014;9(6): e98933.CrossRefPubMedPubMedCentral
12.
Gallagher R. What do patients want from acute migraine treatment? Cephalalgia. 2004;24(Suppl 2):8–15.CrossRefPubMed
13.
Tfelt-Hansen P, Diener HC. Onset of action in placebo-controlled migraine attacks trials: a literature review and recommendation. Cephalalgia. 2021;41(2):148–55.CrossRefPubMed
14.
Li G, Duan S, Zhu T, et al. Efficacy and safety of intranasal agents for the acute treatment of migraine: a systematic review and network meta-analysis. J Headache Pain. 2023;24(1):1–17.CrossRef
15.
Rapoport AM, Bigal ME, Tepper SJ, et al. Intranasal medications for the treatment of migraine and cluster headache. CNS Drugs. 2004;18(10):671–85.CrossRefPubMed
16.
Chaturvedula PV, Mercer SE, Pin SS, et al. Discovery of (R)-N-(3-(7-methyl-1H-indazol-5-yl)-1-(4-(1-methylpiperidin-4-yl)-1-oxopropan-2-yl)-4-(2-oxo-1,2-dihydroquinolin-3-yl)piperidine-1-carboxamide (BMS-742413): a potent human CGRP antagonist with superior safety profile for the treatment of migraine through intranasal delivery. Bioorg Med Chem Lett. 2013;23(11):3157–61.CrossRefPubMed
17.
18.
Durham PL. CGRP-receptor antagonists—a fresh approach to migraine therapy? N Engl J Med. 2004;350(11):1073–5.CrossRefPubMed
19.
Bertz R, Donohue M, Madonia J, et al. Safety, tolerability, and pharmacokinetics of single and multiple ascending doses of intranasal zavegepant in healthy adults [abstract no. S31.004]. Neurology. 2022;98(Suppl 18).
20.
Bertz R, Stringfellow J, Bhardwaj R, et al. Concentration QT interval modeling of intranasally administered zavegepant in healthy subjects [abstract no. P9-12.004]. Neurology. 2023;100(17 Suppl 2):3360.
21.
Bertz R, Bhardwaj R, Donohue M, et al. Effects of zavegepant and concomitant sumatriptan on blood pressure and pharmacokinetics in healthy adult participants [abstract no. P9-12.005]. Neurology. 2023;100(17 Suppl 2):3326.
22.
Boucherie DM, Dammers R, Vincent A, et al. Comparison of gepant effects at therapeutic plasma concentrations: connecting pharmacodynamics and pharmacokinetics. J Headache Pain. 2024;25(1):141.CrossRefPubMedPubMedCentral
23.
Bertz R, Collins J, Bhardwaj R, et al. Comparative bioavailability of single-dose zavegepant nasal spray during and between migraine attacks: a phase 1, randomized, open-label, fixed-sequence, 2-period study [abstract no. P-41]. Headache. 2023;63(Suppl 1):121.
24.
Lipton RB, Croop R, Stock DA, et al. Safety, tolerability, and efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in the USA: a phase 3, double-blind, randomised, placebo-controlled multicentre trial. Lancet Neurol. 2023;22(3):209–17.CrossRefPubMed
25.
Croop R, Madonia J, Stock DA, et al. Zavegepant nasal spray for the acute treatment of migraine: a phase 2/3 double-blind, randomized, placebo-controlled, dose-ranging trial. Headache. 2022;62(9):1153–63.CrossRefPubMedPubMedCentral
26.
Jayasinghe P, O'Sullivan F, Popoff E, et al. Treatment with zavegepant offers improvements in pain severity over 48-hours when compared with placebo—post hoc results from a randomized placebo-controlled trial [abstract no. P9.007 plus poster]. In: 76th Annual Meeting of the American Academy of Neurology. 2024.
27.
Powell L, O'Sullivan F, Jayasinghe P, et al. Examining return to normal function trajectories, a post-hoc analysis of zavegepant [abstract no. P-655]. In: American Headache Society 66th Annual Scientific Meeting. 2024.
28.
Khan ZZ, Ahmed U, Shahzad F, et al. Safety and efficacy of zavegepant in treating migraine: a systematic review. Cureus. 2023;15(7):1–9.
29.
Waqas M, Ansari FUR, Nazir A, et al. Zavegepant nasal spray for the acute treatment of migraine: a meta analysis. Medicine (Baltimore). 2023;102(43): e35632.CrossRefPubMed
30.
Mullin K, Fountaine RF, Linda Mosher L, et al. Efficacy and safety of zavegepant for the acute treatment of migraine in women: results from 2 randomized, placebo-controlled clinical trials [abstract no. P6.004 plus poster]. In: 76th Annual Meeting of the American Academy of Neurology (AAN). 2024.
31.
Armand C, Fountaine R, Mosher L. Efficacy and safety of zavegepant for the acute treatment of migraine in Black/African American adults: results from 2 randomized, placebo-controlled clinical trials [abstract no. P-615]. In: American Headache Society 66th Annual Scientific Meeting. 2024.
32.
Mullin K, Fountaine R, Mosher L. Efficacy and safety of zavegepant for the acute treatment of migraine according to body mass index: results from 2 randomized, placebo-controlled clinical trials [abstract no. P-699]. In: American Headache Society 66th Annual Scientific Meeting. 2024.
33.
Joshi S, Smith T, Pavlovic J, et al. Efficacy of zavegepant nasal spray for the acute treatment of migraine based on triptan treatment experience: pooled results from 2 randomized, placebo-controlled clinical trials [abstract no. P9-12.003]. Neurology. 2023;100(17 Suppl 2):4381.
34.
Pavlovic J, Smith T, Mullin K, et al. Zavegepant 10 mg nasal spray is effective for the acute treatment of migraine regardless of attack frequency: pooled results from 2 randomized, placebo-controlled clinical trials [abstract no. S47.003]. Neurology. 2023;100(17 Suppl 2):4684.
35.
Smith T, Pavlovic J, Mullin K, et al. Zavegepant nasal spray for the acute treatment of migraine with aura and without aura: pooled results from 2 randomized, placebo-controlled clinical trials [abstract no. S47.004]. Neurology. 2023;100(17 Suppl 2):4348.
36.
Croop R, Mosher L, RB. L. Zavegepant 10 mg nasal spray for the acute treatment of migraine in adults with and without baseline nausea: pooled results from two randomized, double-blind placebo-controlled trials [abstract no. P-­257]. Headache. 2023;63(7):1020-1.
37.
Pavlovic JM, Croop R, Mosher L, et al. Efficacy of zavegepant 10 mg nasal spray for the acute treatment of migraine in participants with cardiovascular risk factors [abstract no. P-­249]. Headache. 2023;63(7):1010.
38.
39.
Lipton RB, Mosher L, Croop R. Effect of long-term treatment with zavegepant nasal spray on migraine-related disability: a phase 2/3 open-label, long-term safety trial [abstract no. P-245]. Headache. 2023;63(7):1009.
40.
Pavlovic J, Croop R, L. M. Long-term treatment of migraine with zavegepant nasal spray improves health related quality of life: results from a phase 2/3 open-label, long-term safety trial [abstract no. P-239]. Headache. 2023;63(7):1012–3.
41.
Kudrow D, Mosher L, Straghan E, et al. Acute treatment of migraine with zavegepant nasal spray reduces the use of select analgesics [abstract no. P9.001 plus poster]. In: 76th Annual Meeting of the American Academy of Neurology (AAN). 2024.
42.
Berman G, Mullin K, Pavlovic J, et al. Long-term safety and tolerability of zavegepant 10 mg nasal spray during concomitant use of CGRP monoclonal antibodies: results from a 1-year open- label safety trial [abstract no. P10-12.009]. Neurology. 2023;100(17 Suppl 2):4312.
43.
Pavlovic JM, Croop R, Mosher L, et al. Long-term safety of zavegepant 10 mg in patients with migraine and cardiovascular risk factors. [abstract no. P-250]. Headache. 2023;63(7):1012.
44.
Smith T, Berman G, Fountaine RJ, et al. Long-term safety and tolerability of zavegepant 10 mg nasal spray in the acute treatment of migraine: subgroup analyses [abstract no. P-697]. In: American Headache Society 66th Annual Scientific Meeting. 2024.
45.
Seng E, Buse D, Monteith T, et al. Long-term safety of zavegepant nasal spray for the acute treatment of migraine in adults with a history of anxiety and/or depression and in adults with concomitant use of antidepressants [abstract no. P-675]. In: American Headache Society 66th Annual Scientific Meeting. 2024.
46.
Woodhead JL, Siler SQ, Howell BA, et al. Comparing the liver safety profiles of 4 next-generation CGRP receptor antagonists to the hepatotoxic CGRP inhibitor telcagepant using quantitative systems toxicology modeling. Toxicol Sci. 2022;188(1):108–16.CrossRefPubMedPubMedCentral
47.
Dodick D, Lipton RB, Martin V, et al. Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine. Headache. 2004;44(5):414–25.CrossRefPubMed
Metadata
Title
Zavegepant nasal spray in the acute treatment of migraine: a profile of its use
Author
Yahiya Y. Syed
Publication date
04-01-2025
Publisher
Springer International Publishing
Published in
Drugs & Therapy Perspectives
Print ISSN: 1172-0360
Electronic ISSN: 1179-1977
DOI
https://doi.org/10.1007/s40267-024-01130-4